Ericka M. Ebot
Research Subjects
Ericka M. Ebot has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Garrett M. Frampton
Computational Discovery, Foundation Medicine, Inc., Cambridge, USA
20 shared publications - Meagan Montesion
Computational Discovery, Foundation Medicine Inc, Boston, USA
20 shared publications - Radwa Sharaf
Foundation Medicine Inc., Cambridge, USA
20 shared publications - Afshin Dowlati
University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH
19 shared publications - Caterina I. Colon
Department of Pediatrics, Stanford University, Stanford, California
19 shared publications - Christine M. Lovly
Vanderbilt University Medical Center, Nashville, TN
19 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S22 from Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation
Figure S1: Patterns of tumor mutational burden across different ancestry groups. Figure S2: Spectrum of TP53 and RB1 mutations in SCLC. Figure S3: Gene alteration landscape detected from targeted sequencing of liquid biopsies. Figure S4: Chromosomal loss events are frequent in SCLC and are preferentially enriched for tumor suppressor genes. Figure S5: Hematoxylin & Eosin (H&E) staining for some representative SCLC tumors with rare genomic alterations. Figure S6: Gene alterations detected in SMARCA4-altered SCLC. Figure S7: SCLC tumors exhibit recurrent gene rearrangements with therapeutic potential. Figure S8: Trends of overall survival across different ancestry groups and stage in the clinical cohort. Figure S9: Examination of tumor purity and tumor mutational burden (TMB). Figure S10: Liver and Brain SCLC metastases are enriched for chromosomal arm-level gains compared to lung-biopsied SCLC tumors. Figure S11: SCLC tumors present with unique co-occurring and mutual exclusive patterns of gene alterations. Figure S12: SCLC tumors with wild-type TP53 and/or RB1 have a low tumor mutational burden. Figure S13: SCLC tumors with wild-type TP53 and/or RB1 present with specific gene alterations. Figure S14: A smoking-associated mutational signature is rare in TP53/RB1 WT SCLC tumors. Figure S15: TP53 and RB1 alterations are less frequent in never smokers. Figure S16: Patterns of overall survival based on TP53 and RB1 alteration status. Figure S17: TP53 and RB1 mutations are more frequent in older patients with SCLC. Figure S18: Gene alterations detected in HPV-positive SCLC. Figure S19: Examination of HPV subtypes and prevalence in TP53/RB1 mutant and wild-type SCLC tumors. Figure S20: EGFR-mutant SCLC tumors exhibit unique mutational signature profiles. Figure S21: No overall survival differences based on EGFR mutation status in SCLC. Figure S22: Putative transformed SCLC tumors from EGFR-mutant NSCLC are enriched for EGFR exon 19 deletions.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S22 from Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation
Figure S1: Patterns of tumor mutational burden across different ancestry groups. Figure S2: Spectrum of TP53 and RB1 mutations in SCLC. Figure S3: Gene alteration landscape detected from targeted sequencing of liquid biopsies. Figure S4: Chromosomal loss events are frequent in SCLC and are preferentially enriched for tumor suppressor genes. Figure S5: Hematoxylin & Eosin (H&E) staining for some representative SCLC tumors with rare genomic alterations. Figure S6: Gene alterations detected in SMARCA4-altered SCLC. Figure S7: SCLC tumors exhibit recurrent gene rearrangements with therapeutic potential. Figure S8: Trends of overall survival across different ancestry groups and stage in the clinical cohort. Figure S9: Examination of tumor purity and tumor mutational burden (TMB). Figure S10: Liver and Brain SCLC metastases are enriched for chromosomal arm-level gains compared to lung-biopsied SCLC tumors. Figure S11: SCLC tumors present with unique co-occurring and mutual exclusive patterns of gene alterations. Figure S12: SCLC tumors with wild-type TP53 and/or RB1 have a low tumor mutational burden. Figure S13: SCLC tumors with wild-type TP53 and/or RB1 present with specific gene alterations. Figure S14: A smoking-associated mutational signature is rare in TP53/RB1 WT SCLC tumors. Figure S15: TP53 and RB1 alterations are less frequent in never smokers. Figure S16: Patterns of overall survival based on TP53 and RB1 alteration status. Figure S17: TP53 and RB1 mutations are more frequent in older patients with SCLC. Figure S18: Gene alterations detected in HPV-positive SCLC. Figure S19: Examination of HPV subtypes and prevalence in TP53/RB1 mutant and wild-type SCLC tumors. Figure S20: EGFR-mutant SCLC tumors exhibit unique mutational signature profiles. Figure S21: No overall survival differences based on EGFR mutation status in SCLC. Figure S22: Putative transformed SCLC tumors from EGFR-mutant NSCLC are enriched for EGFR exon 19 deletions.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S24 from Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation
Supplementary Table S1: First-, second-, and third-line systemic therapy in the SCLC clinical cohort. Supplementary Table S2: Genes analyzed as part of this study. Supplementary Table S3: Prevalence of alterations in the genes analyzed. Supplementary Table S4: Prevalence of gene alterations in 81 cases with liquid biopsies. Supplementary Table S5: Chromosomal losses and gains in SCLC. Supplementary Table S6: TET2 loss of function alterations detected in SCLCs. Supplementary Table S7: Manual review of specific mutation subgroups in SCLCs. Supplementary Table S8: Patterns of gene alterations in SMARCA4 altered and wild-type tumors. Supplementary Table S9: Prevalence of gene alterations in rearrangement-positive SCLCs. Supplementary Table S10: Univariate analysis of association between gene alterations and overall surival in the clinical cohort of stage III/IV SCLC tumors. Supplementary Table S11: Patterns of tumor mutational burden based on site of biopsy. Supplementary Table 12: Summary of tumor purity and tumor mutational burden by biopsy site. Supplementary Table S13: Aneuploidy patterns based on site of biopsy. Supplementary Table S14: Comparison of gene alterations in each biopsy site against lung biopsies. Supplementary Table S15: Comparison of gene alterations in liver and brain metastases. Supplementary Table S16: Summary of PTEN alterations in brain and other biopsy sites. Supplementary Table S17: Patterns of co-occurrence and mutual exclusivity between gene alterations in the overall SCLC cohort. Supplementary Table S18: Patterns of gene alterations in TP53 and/or RB1 mutant and wild-type cohorts. Supplementary Table S19: Patterns of gene alterations in young and older patients with SCLC. Supplementary Table S20: Patterns of gene alterations in HPV positive and HPV negative tumors. Supplementary Table S21: Manual review of specific HPV+ SCLCs. Supplementary Table S22: Patterns of gene alterations in STK11 mutant and wild-type cohorts. Supplementary Table S23: Patterns of gene alterations in EGFR mutant and wild-type cohorts. Supplementary Table S24: EGFR kinase domain alterations identified in the overall SCLC cohort.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S24 from Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation
Supplementary Table S1: First-, second-, and third-line systemic therapy in the SCLC clinical cohort. Supplementary Table S2: Genes analyzed as part of this study. Supplementary Table S3: Prevalence of alterations in the genes analyzed. Supplementary Table S4: Prevalence of gene alterations in 81 cases with liquid biopsies. Supplementary Table S5: Chromosomal losses and gains in SCLC. Supplementary Table S6: TET2 loss of function alterations detected in SCLCs. Supplementary Table S7: Manual review of specific mutation subgroups in SCLCs. Supplementary Table S8: Patterns of gene alterations in SMARCA4 altered and wild-type tumors. Supplementary Table S9: Prevalence of gene alterations in rearrangement-positive SCLCs. Supplementary Table S10: Univariate analysis of association between gene alterations and overall surival in the clinical cohort of stage III/IV SCLC tumors. Supplementary Table S11: Patterns of tumor mutational burden based on site of biopsy. Supplementary Table 12: Summary of tumor purity and tumor mutational burden by biopsy site. Supplementary Table S13: Aneuploidy patterns based on site of biopsy. Supplementary Table S14: Comparison of gene alterations in each biopsy site against lung biopsies. Supplementary Table S15: Comparison of gene alterations in liver and brain metastases. Supplementary Table S16: Summary of PTEN alterations in brain and other biopsy sites. Supplementary Table S17: Patterns of co-occurrence and mutual exclusivity between gene alterations in the overall SCLC cohort. Supplementary Table S18: Patterns of gene alterations in TP53 and/or RB1 mutant and wild-type cohorts. Supplementary Table S19: Patterns of gene alterations in young and older patients with SCLC. Supplementary Table S20: Patterns of gene alterations in HPV positive and HPV negative tumors. Supplementary Table S21: Manual review of specific HPV+ SCLCs. Supplementary Table S22: Patterns of gene alterations in STK11 mutant and wild-type cohorts. Supplementary Table S23: Patterns of gene alterations in EGFR mutant and wild-type cohorts. Supplementary Table S24: EGFR kinase domain alterations identified in the overall SCLC cohort.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-5, Supplementary Figures 1-3 from Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions
Table S1. ETS genes with weaker evidence for association with ERG fusion status. Table S2. Androgen receptor transcriptional activity, measured as a más-o-menos score of the Hiernonymus et al. (2006) signature and expressed in standard deviations within a cohort, between ETS-defined subtypes, in TCGA and the Hopkins cohort. Table S3. All genes associated with ERG vs. non-ERG status among the Berglund et al. ETS genes, sorted by increasing p-value in HPFS/PHS. Missing estimates for the validation cohorts (HPFS/PHS and Hopkins) indicate the gene was not measured on the microarrays used in these studies. Table S4. Ratios between Black and White men for ratios of expression between ETS vs. non-ETS tumors. Table S5. Gene set analysis for Hallmark gene sets associated with ERG vs. non-ERG (top), ETS vs. non-ETS (middle), and non-ERG ETS vs. non-ETS status (bottom). Figure S1. Gene expression ratios in TCGA for ETS vs. non-SPOP non-ETS (x axis) and ETS vs. SPOP non-ETS (y-axis). One dot is one tumor. Figure S2. Androgen receptor transcriptional activity by subtype. One dot is one tumor. Figure S3. ETS-related AR target genes.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-5, Supplementary Figures 1-3 from Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions
Table S1. ETS genes with weaker evidence for association with ERG fusion status. Table S2. Androgen receptor transcriptional activity, measured as a más-o-menos score of the Hiernonymus et al. (2006) signature and expressed in standard deviations within a cohort, between ETS-defined subtypes, in TCGA and the Hopkins cohort. Table S3. All genes associated with ERG vs. non-ERG status among the Berglund et al. ETS genes, sorted by increasing p-value in HPFS/PHS. Missing estimates for the validation cohorts (HPFS/PHS and Hopkins) indicate the gene was not measured on the microarrays used in these studies. Table S4. Ratios between Black and White men for ratios of expression between ETS vs. non-ETS tumors. Table S5. Gene set analysis for Hallmark gene sets associated with ERG vs. non-ERG (top), ETS vs. non-ETS (middle), and non-ERG ETS vs. non-ETS status (bottom). Figure S1. Gene expression ratios in TCGA for ETS vs. non-SPOP non-ETS (x axis) and ETS vs. SPOP non-ETS (y-axis). One dot is one tumor. Figure S2. Androgen receptor transcriptional activity by subtype. One dot is one tumor. Figure S3. ETS-related AR target genes.
- Open Access
- 20 November 2025
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (12)
Coverage of actionable alterations in non-small cell lung cancer by hybrid capture-based FoundationOne®CDx compared with amplicon-based OncomineDX
Introduction: FoundationOne®CDx (F1CDx) and Oncomine Dx target test (ODxTT) are commercially available oncology biomarker assays that apply different next-generation sequencing methodologies used to identify predictive markers for therapy selection in non-small cell lung cancer (NSCLC). We hypothesized that F1CDx can detect a higher number of actionable alterations compared with the ODxTT assay. Materials and Methods: We compared the prevalence of genomic alterations (GA) in a real-world NSCLC cohort tested by F1CDx to the theoretical detection by ODxTT, based on publicly available coverage specifications. The clinical actionability of GA was assessed based on NCCN treatment guidelines and FDA oncology drug approvals. Results: KRAS G12C, EGFR mutations, and MET mutations were among the most frequent actionable alterations detected in a large genomic dataset of NSCLC data assayed by the F1CDx test. The ODxTT specifications indicate that ODxTT detects all BRAF and KRAS FDA-approved alterations detected by F1CDx and subsets of the following clinically significant markers: EGFR 83%, RET 76%, ROS1 74%, and ERBB2 38%. In addition, ODxTT had no coverage for actionable genomic findings in ALK, MET, NTRK1/2/3, TMB, or MSI-High status. In this study, the ODxTT assay may fail to report at least one of the clinically actionable biomarkers in 42% of tissue samples compared to F1CDx. Discussion: In summary, in advanced NSCLC, hybrid capture-based NGS, such as F1CDx, may capture more actionable genomic alterations as compared with ODxTT, an amplicon-based NGS.
- 20 November 2025
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 30 (12)
Open AccessCoverage of actionable alterations in non-small cell lung cancer by hybrid capture-based FoundationOne®CDx compared with amplicon-based OncomineDX
Introduction: FoundationOne®CDx (F1CDx) and Oncomine Dx target test (ODxTT) are commercially available oncology biomarker assays that apply different next-generation sequencing methodologies used to identify predictive markers for therapy selection in non-small cell lung cancer (NSCLC). We hypothesized that F1CDx can detect a higher number of actionable alterations compared with the ODxTT assay. Materials and Methods: We compared the prevalence of genomic alterations (GA) in a real-world NSCLC cohort tested by F1CDx to the theoretical detection by ODxTT, based on publicly available coverage specifications. The clinical actionability of GA was assessed based on NCCN treatment guidelines and FDA oncology drug approvals. Results: KRAS G12C, EGFR mutations, and MET mutations were among the most frequent actionable alterations detected in a large genomic dataset of NSCLC data assayed by the F1CDx test. The ODxTT specifications indicate that ODxTT detects all BRAF and KRAS FDA-approved alterations detected by F1CDx and subsets of the following clinically significant markers: EGFR 83%, RET 76%, ROS1 74%, and ERBB2 38%. In addition, ODxTT had no coverage for actionable genomic findings in ALK, MET, NTRK1/2/3, TMB, or MSI-High status. In this study, the ODxTT assay may fail to report at least one of the clinically actionable biomarkers in 42% of tissue samples compared to F1CDx. Discussion: In summary, in advanced NSCLC, hybrid capture-based NGS, such as F1CDx, may capture more actionable genomic alterations as compared with ODxTT, an amplicon-based NGS.
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables and Figures 1 from Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice
Supplementary Tables and Figures
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables and Figures 1 from Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice
Supplementary Tables and Figures
- Open Access
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Data from Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice
Purpose:The purpose of the study was to compare the effectiveness of PARP inhibitor maintenance therapy (mPARPi) in real-world practice by biomarker status [BRCA1/2 alterations (BRCAalt) and a homologous recombination deficiency signature (HRDsig)] in advanced ovarian cancer.Experimental Design:Patients with ovarian cancer receiving first-line platinum-based chemotherapy and either mPARPi or no maintenance were included. Patient data were obtained by a US-based de-identified ovarian cancer Clinico-Genomic Database, from ∼280 US cancer clinics (01/2015–03/2023). Real-world progression-free survival (rwPFS) and overall survival (rwOS) were compared by biomarker status using Cox models, weighted by propensity scores.Results:Of 673 patients, 160 received mPARPi [31.2% BRCAalt and 51.9% HRDsig(+)] and 513 no maintenance [15.6% BRCAalt and 34.1% HRDsig(+)]. BRCAalt patients receiving mPARPi versus no maintenance had favorable rwPFS [HR, 0.48; 95% confidence interval (CI), 0.26–0.87; P = 0.0154], as did BRCA wild-type (WT; HR, 0.76; 95% CI, 0.57–1.01; P = 0.0595). Favorable rwOS was not observed with mPARPi for BRCAalt or BRCA-WT. HRDsig(+) patients receiving mPARPi versus no maintenance had favorable rwPFS (HR, 0.36; 95% CI, 0.24–0.55; P < 0.001) and numerically favorable rwOS (HR, 0.46; 95% CI, 0.21–1.02; P = 0.0561). No differences were observed for HRDsig(−). mPARPi treatment interaction was observed for HRDsig(+) versus HRDsig(−) (rwPFS P < 0.001/rwOS P = 0.016) but not for BRCAalt versus BRCA-WT. Patients with BRCA-WT/HRDsig(+) receiving mPARPi had favorable rwPFS (HR, 0.40; 95% CI, 0.22–0.72; P = 0.003), whereas no difference was observed for BRCA-WT/HRDsig(−).Conclusions:HRDsig predicted benefit of mPARPi better than BRCAalt. Patients with HRDsig(+) status experienced favorable outcomes, even if they had BRCA-WT status. In contrast, patients with HRDsig(−) status did not show significant benefit from mPARPi treatment. HRDsig might predict benefit from mPARPi regardless of BRCAalt status.
- 15 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice
Purpose:The purpose of the study was to compare the effectiveness of PARP inhibitor maintenance therapy (mPARPi) in real-world practice by biomarker status [BRCA1/2 alterations (BRCAalt) and a homologous recombination deficiency signature (HRDsig)] in advanced ovarian cancer.Experimental Design:Patients with ovarian cancer receiving first-line platinum-based chemotherapy and either mPARPi or no maintenance were included. Patient data were obtained by a US-based de-identified ovarian cancer Clinico-Genomic Database, from ∼280 US cancer clinics (01/2015–03/2023). Real-world progression-free survival (rwPFS) and overall survival (rwOS) were compared by biomarker status using Cox models, weighted by propensity scores.Results:Of 673 patients, 160 received mPARPi [31.2% BRCAalt and 51.9% HRDsig(+)] and 513 no maintenance [15.6% BRCAalt and 34.1% HRDsig(+)]. BRCAalt patients receiving mPARPi versus no maintenance had favorable rwPFS [HR, 0.48; 95% confidence interval (CI), 0.26–0.87; P = 0.0154], as did BRCA wild-type (WT; HR, 0.76; 95% CI, 0.57–1.01; P = 0.0595). Favorable rwOS was not observed with mPARPi for BRCAalt or BRCA-WT. HRDsig(+) patients receiving mPARPi versus no maintenance had favorable rwPFS (HR, 0.36; 95% CI, 0.24–0.55; P < 0.001) and numerically favorable rwOS (HR, 0.46; 95% CI, 0.21–1.02; P = 0.0561). No differences were observed for HRDsig(−). mPARPi treatment interaction was observed for HRDsig(+) versus HRDsig(−) (rwPFS P < 0.001/rwOS P = 0.016) but not for BRCAalt versus BRCA-WT. Patients with BRCA-WT/HRDsig(+) receiving mPARPi had favorable rwPFS (HR, 0.40; 95% CI, 0.22–0.72; P = 0.003), whereas no difference was observed for BRCA-WT/HRDsig(−).Conclusions:HRDsig predicted benefit of mPARPi better than BRCAalt. Patients with HRDsig(+) status experienced favorable outcomes, even if they had BRCA-WT status. In contrast, patients with HRDsig(−) status did not show significant benefit from mPARPi treatment. HRDsig might predict benefit from mPARPi regardless of BRCAalt status.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S22 from Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation
Figure S1: Patterns of tumor mutational burden across different ancestry groups. Figure S2: Spectrum of TP53 and RB1 mutations in SCLC. Figure S3: Gene alteration landscape detected from targeted sequencing of liquid biopsies. Figure S4: Chromosomal loss events are frequent in SCLC and are preferentially enriched for tumor suppressor genes. Figure S5: Hematoxylin & Eosin (H&E) staining for some representative SCLC tumors with rare genomic alterations. Figure S6: Gene alterations detected in SMARCA4-altered SCLC. Figure S7: SCLC tumors exhibit recurrent gene rearrangements with therapeutic potential. Figure S8: Trends of overall survival across different ancestry groups and stage in the clinical cohort. Figure S9: Examination of tumor purity and tumor mutational burden (TMB). Figure S10: Liver and Brain SCLC metastases are enriched for chromosomal arm-level gains compared to lung-biopsied SCLC tumors. Figure S11: SCLC tumors present with unique co-occurring and mutual exclusive patterns of gene alterations. Figure S12: SCLC tumors with wild-type TP53 and/or RB1 have a low tumor mutational burden. Figure S13: SCLC tumors with wild-type TP53 and/or RB1 present with specific gene alterations. Figure S14: A smoking-associated mutational signature is rare in TP53/RB1 WT SCLC tumors. Figure S15: TP53 and RB1 alterations are less frequent in never smokers. Figure S16: Patterns of overall survival based on TP53 and RB1 alteration status. Figure S17: TP53 and RB1 mutations are more frequent in older patients with SCLC. Figure S18: Gene alterations detected in HPV-positive SCLC. Figure S19: Examination of HPV subtypes and prevalence in TP53/RB1 mutant and wild-type SCLC tumors. Figure S20: EGFR-mutant SCLC tumors exhibit unique mutational signature profiles. Figure S21: No overall survival differences based on EGFR mutation status in SCLC. Figure S22: Putative transformed SCLC tumors from EGFR-mutant NSCLC are enriched for EGFR exon 19 deletions.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S22 from Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation
Figure S1: Patterns of tumor mutational burden across different ancestry groups. Figure S2: Spectrum of TP53 and RB1 mutations in SCLC. Figure S3: Gene alteration landscape detected from targeted sequencing of liquid biopsies. Figure S4: Chromosomal loss events are frequent in SCLC and are preferentially enriched for tumor suppressor genes. Figure S5: Hematoxylin & Eosin (H&E) staining for some representative SCLC tumors with rare genomic alterations. Figure S6: Gene alterations detected in SMARCA4-altered SCLC. Figure S7: SCLC tumors exhibit recurrent gene rearrangements with therapeutic potential. Figure S8: Trends of overall survival across different ancestry groups and stage in the clinical cohort. Figure S9: Examination of tumor purity and tumor mutational burden (TMB). Figure S10: Liver and Brain SCLC metastases are enriched for chromosomal arm-level gains compared to lung-biopsied SCLC tumors. Figure S11: SCLC tumors present with unique co-occurring and mutual exclusive patterns of gene alterations. Figure S12: SCLC tumors with wild-type TP53 and/or RB1 have a low tumor mutational burden. Figure S13: SCLC tumors with wild-type TP53 and/or RB1 present with specific gene alterations. Figure S14: A smoking-associated mutational signature is rare in TP53/RB1 WT SCLC tumors. Figure S15: TP53 and RB1 alterations are less frequent in never smokers. Figure S16: Patterns of overall survival based on TP53 and RB1 alteration status. Figure S17: TP53 and RB1 mutations are more frequent in older patients with SCLC. Figure S18: Gene alterations detected in HPV-positive SCLC. Figure S19: Examination of HPV subtypes and prevalence in TP53/RB1 mutant and wild-type SCLC tumors. Figure S20: EGFR-mutant SCLC tumors exhibit unique mutational signature profiles. Figure S21: No overall survival differences based on EGFR mutation status in SCLC. Figure S22: Putative transformed SCLC tumors from EGFR-mutant NSCLC are enriched for EGFR exon 19 deletions.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Data from Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation
Small cell lung cancer (SCLC) is a recalcitrant neuroendocrine carcinoma with dismal survival outcomes. A major barrier in the field has been the relative paucity of human tumors studied. Here we provide an integrated analysis of 3,600 “real-world” SCLC cases. This large cohort allowed us to identify new recurrent alterations and genetic subtypes, including STK11-mutant tumors (1.7%) and TP53/RB1 wild-type tumors (5.5%), as well as rare cases that were human papillomavirus-positive. In our cohort, gene amplifications on 4q12 are associated with increased overall survival while CCNE1 amplification is associated with decreased overall survival. We also identify more frequent alterations in the PTEN pathway in brain metastases. Finally, profiling cases of SCLC containing oncogenic drivers typically associated with NSCLC demonstrates that SCLC transformation may occur across multiple distinct molecular cohorts of NSCLC. These novel and unsuspected genetic features of SCLC may help personalize treatment approaches for this fatal form of cancer.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation
Small cell lung cancer (SCLC) is a recalcitrant neuroendocrine carcinoma with dismal survival outcomes. A major barrier in the field has been the relative paucity of human tumors studied. Here we provide an integrated analysis of 3,600 “real-world” SCLC cases. This large cohort allowed us to identify new recurrent alterations and genetic subtypes, including STK11-mutant tumors (1.7%) and TP53/RB1 wild-type tumors (5.5%), as well as rare cases that were human papillomavirus-positive. In our cohort, gene amplifications on 4q12 are associated with increased overall survival while CCNE1 amplification is associated with decreased overall survival. We also identify more frequent alterations in the PTEN pathway in brain metastases. Finally, profiling cases of SCLC containing oncogenic drivers typically associated with NSCLC demonstrates that SCLC transformation may occur across multiple distinct molecular cohorts of NSCLC. These novel and unsuspected genetic features of SCLC may help personalize treatment approaches for this fatal form of cancer.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S24 from Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation
Supplementary Table S1: First-, second-, and third-line systemic therapy in the SCLC clinical cohort. Supplementary Table S2: Genes analyzed as part of this study. Supplementary Table S3: Prevalence of alterations in the genes analyzed. Supplementary Table S4: Prevalence of gene alterations in 81 cases with liquid biopsies. Supplementary Table S5: Chromosomal losses and gains in SCLC. Supplementary Table S6: TET2 loss of function alterations detected in SCLCs. Supplementary Table S7: Manual review of specific mutation subgroups in SCLCs. Supplementary Table S8: Patterns of gene alterations in SMARCA4 altered and wild-type tumors. Supplementary Table S9: Prevalence of gene alterations in rearrangement-positive SCLCs. Supplementary Table S10: Univariate analysis of association between gene alterations and overall surival in the clinical cohort of stage III/IV SCLC tumors. Supplementary Table S11: Patterns of tumor mutational burden based on site of biopsy. Supplementary Table 12: Summary of tumor purity and tumor mutational burden by biopsy site. Supplementary Table S13: Aneuploidy patterns based on site of biopsy. Supplementary Table S14: Comparison of gene alterations in each biopsy site against lung biopsies. Supplementary Table S15: Comparison of gene alterations in liver and brain metastases. Supplementary Table S16: Summary of PTEN alterations in brain and other biopsy sites. Supplementary Table S17: Patterns of co-occurrence and mutual exclusivity between gene alterations in the overall SCLC cohort. Supplementary Table S18: Patterns of gene alterations in TP53 and/or RB1 mutant and wild-type cohorts. Supplementary Table S19: Patterns of gene alterations in young and older patients with SCLC. Supplementary Table S20: Patterns of gene alterations in HPV positive and HPV negative tumors. Supplementary Table S21: Manual review of specific HPV+ SCLCs. Supplementary Table S22: Patterns of gene alterations in STK11 mutant and wild-type cohorts. Supplementary Table S23: Patterns of gene alterations in EGFR mutant and wild-type cohorts. Supplementary Table S24: EGFR kinase domain alterations identified in the overall SCLC cohort.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S24 from Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation
Supplementary Table S1: First-, second-, and third-line systemic therapy in the SCLC clinical cohort. Supplementary Table S2: Genes analyzed as part of this study. Supplementary Table S3: Prevalence of alterations in the genes analyzed. Supplementary Table S4: Prevalence of gene alterations in 81 cases with liquid biopsies. Supplementary Table S5: Chromosomal losses and gains in SCLC. Supplementary Table S6: TET2 loss of function alterations detected in SCLCs. Supplementary Table S7: Manual review of specific mutation subgroups in SCLCs. Supplementary Table S8: Patterns of gene alterations in SMARCA4 altered and wild-type tumors. Supplementary Table S9: Prevalence of gene alterations in rearrangement-positive SCLCs. Supplementary Table S10: Univariate analysis of association between gene alterations and overall surival in the clinical cohort of stage III/IV SCLC tumors. Supplementary Table S11: Patterns of tumor mutational burden based on site of biopsy. Supplementary Table 12: Summary of tumor purity and tumor mutational burden by biopsy site. Supplementary Table S13: Aneuploidy patterns based on site of biopsy. Supplementary Table S14: Comparison of gene alterations in each biopsy site against lung biopsies. Supplementary Table S15: Comparison of gene alterations in liver and brain metastases. Supplementary Table S16: Summary of PTEN alterations in brain and other biopsy sites. Supplementary Table S17: Patterns of co-occurrence and mutual exclusivity between gene alterations in the overall SCLC cohort. Supplementary Table S18: Patterns of gene alterations in TP53 and/or RB1 mutant and wild-type cohorts. Supplementary Table S19: Patterns of gene alterations in young and older patients with SCLC. Supplementary Table S20: Patterns of gene alterations in HPV positive and HPV negative tumors. Supplementary Table S21: Manual review of specific HPV+ SCLCs. Supplementary Table S22: Patterns of gene alterations in STK11 mutant and wild-type cohorts. Supplementary Table S23: Patterns of gene alterations in EGFR mutant and wild-type cohorts. Supplementary Table S24: EGFR kinase domain alterations identified in the overall SCLC cohort.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S22 from Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation
Figure S1: Patterns of tumor mutational burden across different ancestry groups. Figure S2: Spectrum of TP53 and RB1 mutations in SCLC. Figure S3: Gene alteration landscape detected from targeted sequencing of liquid biopsies. Figure S4: Chromosomal loss events are frequent in SCLC and are preferentially enriched for tumor suppressor genes. Figure S5: Hematoxylin & Eosin (H&E) staining for some representative SCLC tumors with rare genomic alterations. Figure S6: Gene alterations detected in SMARCA4-altered SCLC. Figure S7: SCLC tumors exhibit recurrent gene rearrangements with therapeutic potential. Figure S8: Trends of overall survival across different ancestry groups and stage in the clinical cohort. Figure S9: Examination of tumor purity and tumor mutational burden (TMB). Figure S10: Liver and Brain SCLC metastases are enriched for chromosomal arm-level gains compared to lung-biopsied SCLC tumors. Figure S11: SCLC tumors present with unique co-occurring and mutual exclusive patterns of gene alterations. Figure S12: SCLC tumors with wild-type TP53 and/or RB1 have a low tumor mutational burden. Figure S13: SCLC tumors with wild-type TP53 and/or RB1 present with specific gene alterations. Figure S14: A smoking-associated mutational signature is rare in TP53/RB1 WT SCLC tumors. Figure S15: TP53 and RB1 alterations are less frequent in never smokers. Figure S16: Patterns of overall survival based on TP53 and RB1 alteration status. Figure S17: TP53 and RB1 mutations are more frequent in older patients with SCLC. Figure S18: Gene alterations detected in HPV-positive SCLC. Figure S19: Examination of HPV subtypes and prevalence in TP53/RB1 mutant and wild-type SCLC tumors. Figure S20: EGFR-mutant SCLC tumors exhibit unique mutational signature profiles. Figure S21: No overall survival differences based on EGFR mutation status in SCLC. Figure S22: Putative transformed SCLC tumors from EGFR-mutant NSCLC are enriched for EGFR exon 19 deletions.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S22 from Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation
Figure S1: Patterns of tumor mutational burden across different ancestry groups. Figure S2: Spectrum of TP53 and RB1 mutations in SCLC. Figure S3: Gene alteration landscape detected from targeted sequencing of liquid biopsies. Figure S4: Chromosomal loss events are frequent in SCLC and are preferentially enriched for tumor suppressor genes. Figure S5: Hematoxylin & Eosin (H&E) staining for some representative SCLC tumors with rare genomic alterations. Figure S6: Gene alterations detected in SMARCA4-altered SCLC. Figure S7: SCLC tumors exhibit recurrent gene rearrangements with therapeutic potential. Figure S8: Trends of overall survival across different ancestry groups and stage in the clinical cohort. Figure S9: Examination of tumor purity and tumor mutational burden (TMB). Figure S10: Liver and Brain SCLC metastases are enriched for chromosomal arm-level gains compared to lung-biopsied SCLC tumors. Figure S11: SCLC tumors present with unique co-occurring and mutual exclusive patterns of gene alterations. Figure S12: SCLC tumors with wild-type TP53 and/or RB1 have a low tumor mutational burden. Figure S13: SCLC tumors with wild-type TP53 and/or RB1 present with specific gene alterations. Figure S14: A smoking-associated mutational signature is rare in TP53/RB1 WT SCLC tumors. Figure S15: TP53 and RB1 alterations are less frequent in never smokers. Figure S16: Patterns of overall survival based on TP53 and RB1 alteration status. Figure S17: TP53 and RB1 mutations are more frequent in older patients with SCLC. Figure S18: Gene alterations detected in HPV-positive SCLC. Figure S19: Examination of HPV subtypes and prevalence in TP53/RB1 mutant and wild-type SCLC tumors. Figure S20: EGFR-mutant SCLC tumors exhibit unique mutational signature profiles. Figure S21: No overall survival differences based on EGFR mutation status in SCLC. Figure S22: Putative transformed SCLC tumors from EGFR-mutant NSCLC are enriched for EGFR exon 19 deletions.